Business Context and Reporting Period
Company: Accuray Incorporated
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2010
Business Overview: Accuray designs, develops, and sells the CyberKnife system, an image-guided robotic radiosurgery system used for treating solid tumors. The company operates globally with subsidiaries in Europe, Asia, and the Americas. As of March 31, 2010, there were 196 CyberKnife systems installed at customer sites.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Mar 31, 2010 | Nine Months Ended Mar 31, 2010 | Balance Sheet (Mar 31, 2010) |
|---|---|---|---|
| Total Net Revenue | $51,940 | $159,837 | - |
| Gross Profit | $25,376 | $72,960 | - |
| Gross Margin | 48.9% | 45.6% | - |
| Net Income (Loss) | $2,272 | $(2,179) | - |
| Operating Income (Loss) | $2,759 | $(3,160) | - |
| Cash and Cash Equivalents | - | - | $36,036 |
| Total Marketable Securities | - | - | $87,901 |
| Total Assets | - | - | $257,975 |
| Total Liabilities | - | - | $96,283 |
| Accumulated Deficit | - | - | $(122,696) |
Material Changes vs. Prior Period
- Revenue Decline: Total net revenue decreased 15% ($9.4 million) for the three months ended March 31, 2010, compared to the same period in 2009. Product revenue dropped 18%, and shared ownership revenue fell 62%. However, service revenue remained relatively stable, declining only 2%.
- Profitability Improvement (Quarterly): The company reported a net income of $2.3 million for the quarter, compared to $1.2 million in the prior year quarter. This was driven by a significant reduction in operating expenses.
- Expense Reductions: Selling and marketing expenses decreased 37% ($4.2 million) and Research and Development expenses decreased 17% ($1.5 million) compared to the prior year quarter. These reductions were primarily due to a workforce alignment plan executed in fiscal year 2009 and reduced stock-based compensation.
- Cash Flow: Net cash used in operating activities was $12.9 million for the nine months ended March 31, 2010, compared to $9.9 million in the prior year period. This was largely due to a decrease in deferred revenue and accounts payable.
Guidance, Outlook, and Risks
- Revenue Recognition Shift: Management anticipates that revenue from legacy "Platinum" service plans (which require deferral until upgrade obligations are met) will decrease in future periods, while non-Platinum revenue and service revenue are expected to grow as the installed base expands.
- Investment Liquidity: The company holds approximately $21.5 million in Auction-Rate Securities (ARS) classified as trading securities. These securities have failed at auction. The company has a "Rights Agreement" with UBS allowing it to sell these securities at par value between June 30, 2010, and July 2, 2012. Management expects to exercise this option on June 30, 2010.
- Legal Proceedings: The company is subject to a consolidated securities class action lawsuit and consolidated shareholder derivative lawsuits alleging false or misleading statements regarding operations. No liabilities have been recorded as losses are not considered probable or estimable.
- Regulatory and Reimbursement Risks: The company faces risks related to Medicare reimbursement rates, which were modestly lower in 2010. Additionally, new healthcare reform legislation (Patient Protection and Affordable Care Act) may impact demand and reimbursement.
- Backlog: As of March 31, 2010, backlog included $125 million for systems, $18 million for shared ownership systems, and $207 million for service coverage.
Key Facts for Investor Verification
- Platinum Plan Revenue Recognition: Verify the timeline for satisfying upgrade obligations on legacy Platinum plans, as this dictates when significant deferred revenue will be recognized.
- ARS Liquidity Strategy: Confirm the execution of the sale of Auction-Rate Securities to UBS on June 30, 2010, to ensure the realization of par value and removal of liquidity risk.
- Service Revenue Growth: Monitor the growth rate of non-Platinum service revenue as a key indicator of the expanding installed base and recurring revenue stability.
- Legal Exposure: Track the status of the consolidated securities class action and derivative lawsuits for potential settlement costs or reputational impact.
- Reimbursement Rates: Assess the long-term impact of the 2010 Medicare rate reductions and the 2.3% excise tax on medical devices (effective 2013) on customer purchasing power.